The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Diagnosis and management of multiple myeloma: a review
Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
SV Rajkumar - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the …
M D'agostino, DA Cairns, JJ Lahuerta… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
Global burden of hematologic malignancies and evolution patterns over the past 30 years
N Zhang, J Wu, Q Wang, Y Liang, X Li, G Chen… - Blood Cancer …, 2023 - nature.com
Hematologic malignancies are among the most common cancers, and understanding their
incidence and death is crucial for targeting prevention, clinical practice improvement, and …
incidence and death is crucial for targeting prevention, clinical practice improvement, and …
[HTML][HTML] Multiple myeloma current treatment algorithms
SV Rajkumar, S Kumar - Blood cancer journal, 2020 - nature.com
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
Epidemiology, staging, and management of multiple myeloma
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world,
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …